Sandia Holdings’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Sandia Holdings’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-927,264	Closed	-$3.43M	–	28
2017 Q4	$3.43M	Hold	927,264	–	–	1.57%	24
2017 Q3	$3.79M	Hold	927,264	–	–	1.63%	24
2017 Q2	$3.44M	Buy	927,264 +383,545	+71%	+$1.52M	1.61%	22
2017 Q1	$2.25M	Hold	543,719	–	–	1.13%	21
2016 Q4	$2.34M	Buy	+543,719	New	+$3.51M	1.27%	21

Sandia Holdings's CASC Position: Q1 2018 in Review

Sandia Holdings sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 927,264 shares — an estimated $3.43M sold.

Sandia Holdings first reported a position in CASC in Q4 2016 and held it in 5 quarters. The position peaked at $3.79M in Q3 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

Sandia Holdings reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Sandia Holdings sold 927,264 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $3.43M.
Sandia Holdings first reported a position in Cascadian Therapeutics, Inc. in Q4 2016 and held it in 5 quarters.
Sandia Holdings's Cascadian Therapeutics, Inc. position peaked at $3.79M in Q3 2017.
1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Sandia Holdings's 13F filing for Q1 2018, filed 11 May 2018.